GENE ONLINE|News &
Opinion
Blog

2021-11-10| Special

Experts Weigh on How COVID Vaccine Development Has Prepared Us for the Next Pandemic

by Sahana Shankar
Share To
The COVID-19 pandemic was a major disruptive force to propel major innovation, scale, and capacity building in vaccine development. The last two years have seen an unprecedented acceleration in vaccine research, regulatory approvals, and consumer readiness. In a panel discussion titled “Future of Vaccines’,  at the Financial Times Global Pharmaceutical and Biotechnology Conference, industry experts shared their lessons from the COVID-19 pandemic.

The panel, moderated by Greg Reh, Global Life Sciences and Healthcare Industry leader, Deloitte, comprised of

Judy Stewart, Senior Vice President, Head of US vaccines, GlaxoSmithKline Lovisa Afzelius, Origination Partner, Flagship Pioneering Nell Beattie, Chief Business Officer, VBI Vaccines Rasmus Bech Hansen, Co-Founder, and CEO, Airfinity

It's free! Log in now to read

LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top